NASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free TERN Stock Alerts $6.01 -1.01 (-14.39%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$5.72▼$7.1050-Day Range$4.54▼$7.1052-Week Range$3.26▼$13.03Volume2.10 million shsAverage Volume730,722 shsMarket Capitalization$388.73 millionP/E RatioN/ADividend YieldN/APrice Target$14.94 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Terns Pharmaceuticals alerts: Email Address Terns Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside148.5% Upside$14.94 Price TargetShort InterestHealthy5.19% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment1.35Based on 6 Articles This WeekInsider TradingSelling Shares$2.12 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.39 out of 5 starsMedical Sector122nd out of 928 stocksPharmaceutical Preparations Industry45th out of 437 stocks 3.4 Analyst's Opinion Consensus RatingTerns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTerns Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Terns Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.19% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 50.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTerns Pharmaceuticals has received a 58.77% net impact score from Upright. Terns Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Terns Pharmaceuticals is -0.95. Previous Next 3.5 News and Social Media Coverage News SentimentTerns Pharmaceuticals has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Terns Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,122,017.00 in company stock.Percentage Held by Insiders15.10% of the stock of Terns Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Terns Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.41) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Terns Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Terns Pharmaceuticals Stock (NASDAQ:TERN)Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Read More TERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TERN Stock News HeadlinesMay 30 at 8:05 AM | globenewswire.comTerns Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 17, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in UBS Obesity Therapeutics DayMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)May 14, 2024 | markets.businessinsider.comHold Rating on Terns Pharmaceuticals Pending Clinical Trial OutcomesMay 13, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 13, 2024 | finance.yahoo.comTerns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss ProjectionsMay 13, 2024 | globenewswire.comTerns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | globenewswire.comTerns Pharmaceuticals Announces Leadership ChangesMay 7, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024May 3, 2024 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)April 30, 2024 | markets.businessinsider.comBuy Rating Reiterated for ARQT Amidst Strong Zoryve Performance and Market ResilienceApril 29, 2024 | globenewswire.comTerns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive DifferentiationApril 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Terns Pharmaceuticals Based on TERN-701 Market Potential and StrategyApril 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)April 18, 2024 | morningstar.comTerns Pharmaceuticals Inc Ordinary SharesApril 11, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerApril 10, 2024 | globenewswire.comTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerApril 9, 2024 | msn.comMadrigal announces US launch of NASH/MASH drug RezdiffraApril 5, 2024 | investing.comVivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 millionMarch 30, 2024 | morningstar.comThis small-cap stock is expected to take off - if its weight-loss pill trial succeedsMarch 28, 2024 | marketwatch.comThis small-cap stock is expected to take off — if its weight-loss pill trial succeedsMarch 27, 2024 | msn.comHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime SoonMarch 25, 2024 | investorplace.comWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichMarch 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial StabilityMarch 16, 2024 | finance.yahoo.comTERN Apr 2024 15.000 callSee More Headlines Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today6/01/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TERN CUSIPN/A CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Target$14.94 High Stock Price Target$23.00 Low Stock Price Target$5.50 Potential Upside/Downside+148.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.54% Return on Assets-33.83% Debt Debt-to-Equity RatioN/A Current Ratio27.85 Quick Ratio27.85 Sales & Book Value Annual Sales$1 million Price / Sales388.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.64Miscellaneous Outstanding Shares64,680,000Free Float54,911,000Market Cap$388.73 million OptionableNot Optionable Beta-0.49 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Erin Quirk M.D. (Age 53)President & Head of Research & Development Comp: $1.06MDr. Mark Joseph Vignola Ph.D. (Age 46)CFO & Treasurer Comp: $974.16kMr. Seokho Yoon Esq. (Age 46)COO, General Counsel & Secretary Comp: $921.05kMs. Amy L. Burroughs M.B.A. (Age 53)CEO & Director Dr. Jeffrey R. Jasper Ph.D.Senior VP & Head of ResearchDr. Emil T. Kuriakose M.D. (Age 44)Chief Medical Officer Ms. Melita Sun Jung (Age 47)Chief Business Officer More ExecutivesKey CompetitorsAquestive TherapeuticsNASDAQ:AQSTInozyme PharmaNASDAQ:INZYEnanta PharmaceuticalsNASDAQ:ENTAEnzo BiochemNYSE:ENZNextCureNASDAQ:NXTCView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 44,307 shares on 5/20/2024Ownership: 0.069%Ikarian Capital LLCSold 76,983 shares on 5/17/2024Ownership: 0.137%Walleye Trading LLCBought 15,000 shares on 5/17/2024Ownership: 0.023%California State Teachers Retirement SystemSold 4,884 shares on 5/16/2024Ownership: 0.050%Kennedy Capital Management LLCBought 15,466 shares on 5/16/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions TERN Stock Analysis - Frequently Asked Questions Should I buy or sell Terns Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TERN shares. View TERN analyst ratings or view top-rated stocks. What is Terns Pharmaceuticals' stock price target for 2024? 8 Wall Street analysts have issued twelve-month price objectives for Terns Pharmaceuticals' stock. Their TERN share price targets range from $5.50 to $23.00. On average, they expect the company's share price to reach $14.94 in the next twelve months. This suggests a possible upside of 148.5% from the stock's current price. View analysts price targets for TERN or view top-rated stocks among Wall Street analysts. How have TERN shares performed in 2024? Terns Pharmaceuticals' stock was trading at $6.49 on January 1st, 2024. Since then, TERN shares have decreased by 7.4% and is now trading at $6.01. View the best growth stocks for 2024 here. Are investors shorting Terns Pharmaceuticals? Terns Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,230,000 shares, a decrease of 50.3% from the April 30th total of 4,490,000 shares. Based on an average daily trading volume, of 933,600 shares, the days-to-cover ratio is presently 2.4 days. Currently, 5.2% of the shares of the stock are sold short. View Terns Pharmaceuticals' Short Interest. When is Terns Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our TERN earnings forecast. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.29) EPS for the quarter, hitting the consensus estimate of ($0.29). When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO. Who are Terns Pharmaceuticals' major shareholders? Terns Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.40%), Janus Henderson Group PLC (3.10%), Russell Investments Group Ltd. (0.98%), Affinity Asset Advisors LLC (0.70%), Ikarian Capital LLC (0.14%) and Swiss National Bank (0.09%). Insiders that own company stock include Biosciences Fund V LP Lav, Hongbo Lu, Orbimed Advisors Llc and Vivo Opportunity, Llc. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TERN) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
